Articles tagged "Kidney transplantation"

2015 American Transplant Congress
Belatacept-Treated Patients Had Better Graft Survival at 7-Years Post-Transplant Compared With Cyclosporine-Treated Patients: Final Results from BENEFIT
F. Vincenti,¹ J. Grinyó,² L. Rostaing,³ K. Rice,⁴ S. Steinberg,⁵ M. Moal,⁶ M. Polinsky,⁷ U. Meier-Kriesche,⁷ C. Larsen.⁸
¹Univ of Calif, San Francisco; ²Univ Hosp Bellvitge, Barcelona, Spain; ³Univ Hosp and INSERM U563,IFR-BMT, Toulouse, France; ⁴Baylor Univ Med Ctr, Dallas; ⁵Sharp Memorial Hosp, San Diego; ⁶Hôp de La Cavale Blanche, Brest, France; ⁷BMS, Lawrenceville; ⁸Emory Univ Transpl Ctr, Atlanta.
Background: At 3yrs, improvement in renal function was seen in kidney transplant recipients treated with belatacept (bela) vs cyclosporine (CsA) in BENEFIT. Here we report…
2015 American Transplant Congress
Plasmapheresis – A Previously Unrecognised Risk Factor for BK Viraemia
E. Olayos,¹ K. Barraclough,² R. Walker,³ R. Masterson,² H. Peter,² C. Solomon.⁴
¹St Vincents Hospital, Fitroy, Victoria, Australia; ²Nephrology, Royal Melbourne Hospital, Parkville, Victoria, Australia; ³Nephrology, The Alfred Hospital, Prahran, Victoria, Australia; ⁴Nephrology, Western Hospital, Footscray, Victoria, Australia.
BK nephropathy is an important preventable cause of graft loss, with the only universally accepted risk factor being overall burden of immunosuppression. In the absence…
2015 American Transplant Congress
Recurrent IgA Nephropathy in Kidney Transplant Recipients Receiving a Steroid Sparing Immunosuppression Protocol
K. Koutroutsos,¹ R. Charif,¹ D. Goodall,¹ C. Roufosse,² J. Galliford,¹ T. Cook,² D. Taube,¹ M. Loucaidou.¹
¹Kidney and Transplant Centre, Imperial Healthcare NHS Trust, London, United Kingdom; ²Department of Histopathology, Imperial Healthcare NHS Trust, London, United Kingdom.
Background: Steroid sparing immunosuppression is increasingly used in order to avoid the many well-known side effects of steroids. It has been argued that steroid use…
2015 American Transplant Congress
Outcomes of Eculizumab (ANTI-C5) Therapy for Treatment of Refractory Antiobdy-Mediated Rejection (ABMR) and Thrombotic Microangiopathy (TMA)
P. Wongsaroj,¹ J. Choi,¹ A. Vo,¹ J. Kahwaji,¹ A. Peng,¹ R. Villicana,¹ M. Haas,² S. Jordan.¹
¹Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA; ²Pathology, Cedars-Sinai Medical Center, Los Angeles, CA.
Introduction: ABMR results from DSA binding to donor endothelium initiating the classical complement pathway. This results in the formation of terminal MAC (C5b-C9) complex and…
2015 American Transplant Congress
Cyclophosphamide as a Salvage Therapy for Combined Intravenous Immunoglobulins and Plasmapheresis Refractory Antibody-Mediated Rejection
W. Habhab,¹ A. Dada,² M. Alwassia,¹ N. Baz,² N. Zabani,¹ A. Fahmy,¹ A. Abdul Malik.¹
¹Nephrology, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia; ²Pathlogy, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia.
Acute antibody-mediated rejection (AMR) poses a significant risk to graft survival. Current or standard treatment (ST) of AMR currently consists of plasmapheresis (PP), intravenous immunoglobulin…
2015 American Transplant Congress
IL-17 Production Influenced by Induction Therapy With ATG
D. Abendroth,¹ M. Marzinzig,¹ J. Kaden.²
¹Center of Surgery, University of Ulm, Ulm, Germany; ²Renal Transplant Center, Municipal Friedrichshain Hospital, Berlin, Germany.
Introduction Immune-mediated rejection remains the most important cause of graft failure. Recently, a newly identified CD4+ T cell subset, Th17, distinct from Th1 or Th2,…
2015 American Transplant Congress
Diabetes Mellitus and Prediabetes On Kidney Transplant Waiting List – Prevalence, Metabolic Phenotyping and Risk Stratification Approach
M. Guthoff,¹ D. Vosseler,¹ J. Langanke,¹ S. Nadalin,² A. Königsrainer,² H.-U. Häring,¹ A. Fritsche,¹ N. Heyne.¹
¹Dept. of Endocrinology and Diabetology, Angiology, Nephrology and Clinical Chemistry, University of Tübingen, Tübingen, Germany; ²Dept. of General, Visceral and Transplant Surgery, University of Tübingen, Tübingen, Germany.
Purpose: Diabetes mellitus (DM), the most common cause of ESRD, limits access to transplantation and impairs patient and allograft outcome. Prediabetes is an independent risk…
2015 American Transplant Congress
Burden of Early Antibody-Mediated Rejection (AMR): Complications, Resource Utilization and Cost-Differential in Treatment of AMR
R. Banga,¹ C. Schinstock,¹ A. Boscoe,⁴ M. Hathcock,³ W. Kremers,³ M. Stegall.²
¹Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN; ²Division of Transplantation Surgery, Mayo Clinic, Rochester, MN; ³Division of Biostatistics, Mayo Clinic, Rochester, MN; ⁴Health Outcomes Research, Alexion Pharmaceuticals, Cheshire, CT.
Early antibody-mediated rejection (AMR) is common in positive crossmatch kidney transplants (+XMKTx). The current study determined the complications, resource utilization and cost associated with early,…
2015 American Transplant Congress
Is the Pulsatile Kidney Preservation Machine a Vaulable Tool in Evaluating Kidney Suitability from Older Donors After Brain Death?
D. Paredes Zapata,¹ A. Ruiz Arranz,¹ C. Rodriguez Villar,¹ L. Peri Cussi,² A. Alcaraz Asensio,² R. Adalia Bartolome,¹ F. Oppenheimer Salinas.³
¹Donation and Transplant Coordination Section, Hospital Clinic, University of Barcelona, Barcelona, Spain; ²Urology Department, Hospital Clinic, University of Barcelona, Barcelona, Spain; ³Renal Transplant Unit, Hospital Clinic, Barcelona, Spain.
Introduction: Donors after Brain Death (DBD) older than 60 years old, have become 46.8% of our donor activity, with higher Discard Rate (DR). Assessment of…
2015 American Transplant Congress
MYH9 Polymorphic Variants and Chronic Lesions in Transplanted Kidney Biopsy
J. Pazik,¹ M. Oldak,² Z. Lewandowski,³ D. Ozieblo,⁴ K. Michalska,⁵ A. Perkowska Ptasińska,¹ A. Sadowska,¹ M. Nowaczyk,⁵ J. Malejczyk,⁴ M. Durlik.¹
¹Department of Nephrology and Transplantation Medicine, Medical University of Warsaw, Warsaw, Poland; ²Institute of Physiology and Pathology of Hearing, Warsaw, Poland; ³Department of Epidemiology, Medical University of Warsaw, Warsaw, Poland; ⁴Department of Histology and Embryology, Medical University of Warsaw, Warsaw, Poland; ⁵Department of Clinical Immunology, Medical University of Warsaw, Warsaw, Poland.
MYH9 encoding a non-muscle myosin heavy chain IIA is expressed in podocytes, mesangial, tubular, capillary endothelial cells and vascular wall. Intronic variants of MYH9 associate…